Skip to content
DraconiticResearch
Search Sources API
203,203 studies31 sourcesUpdated 11 min ago
Peer-reviewedCC BY 4.0Diabetes, Obesity & Metabolism

Defining Weight‐Loss‐Independent Hepatic Effects of Incretin‐Based Therapies

  • Mingyuan Zhang1,2,3
  • Hanyang Liu1
  • Yawen Hao1
  • Lanlan Chen1,3,4
4 affiliations
  1. 1Department of Hepatology and Gastroenterology Charité—Universitätsmedizin Berlin, Campus Virchow‐Klinikum (CVK) and Campus Charité Mitte (CCM) Berlin Germany
  2. 2Department of Hepatology, Jilin Provincial Key Laboratory of Metabolic Liver Diseases The First Hospital of Jilin University, Jilin University Changchun China
  3. 3China‐Singapore Belt and Road Joint Laboratory on Liver Disease Research The First Hospital of Jilin University, Jilin University Changchun China
  4. 4Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center The First Hospital of Jilin University Changchun China
Read full textPDFDOICite

Related

  1. Beyond Weight Loss and Glycemic Control: Molecular Mechanisms and Hypothesis-Generating Therapeutic Potential of Incretin-Based Therapies Against Peritoneal Fibrosis in Peritoneal Dialysis.
    Yi-Chen Li, Jui-Ting Hsu, Chung-Ming Fu +13
    Pharmaceuticals (Basel, Switzerland)Peer-reviewedCC BYFull textGeneral medicineEurope PMC
  2. Accuracy, potential harm, weight stigma, and commercial influence in short-form social media content on incretin-based therapies for obesity
    Yeo-Jun Yoon, Amanda Velazquez, Sehej-Leen Parmar +9
    Frontiers in endocrinologyPeer-reviewedCC BYFull textEndocrinology & metabolismEurope PMCCrossref
  3. Cardiometabolic Substrate Modification in Atrial Fibrillation: Obesity and Epicardial Adipose Tissue in the Era of Incretin-Based Therapies and Catheter Ablation
    Andrea Matteucci, Michela Bonanni, Luca Sgarra +7
    Journal of cardiovascular development and diseasePeer-reviewedCC BYFull textCardiovascular medicineEurope PMC
  4. Continuous glucose monitoring after discontinuation of incretin-based obesity pharmacotherapy: indirect evidence and a research framework for metabolic stability and weight maintenance
    Andrijana Koceva, Andrej Janez, Mojca Jensterle
    Frontiers in endocrinologyPeer-reviewedCC BYFull textEndocrinology & metabolismEurope PMC
  5. Practical Challenges of Switching and Cross-Titration Between Incretin-Based Therapies in Type 2 Diabetes and Obesity: A Narrative Review
    Jana Makuc, Miodrag Janić
    Journal of Clinical MedicinePeer-reviewedCC BY 4.0Endocrinology & metabolismCrossref

Cite

BibTeXRIS
BibTeX
@article{zhang2026defining,
  title = {{Defining Weight‐Loss‐Independent Hepatic Effects of Incretin‐Based Therapies}},
  author = {Mingyuan Zhang and Hanyang Liu and Yawen Hao and Lanlan Chen},
  journal = {Diabetes, Obesity \& Metabolism},
  year = {2026},
  month = sep,
  doi = {10.1111/dom.71391},
  url = {https://doi.org/10.1111/dom.71391},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Defining Weight‐Loss‐Independent Hepatic Effects of Incretin‐Based Therapies
AU  - Mingyuan Zhang
AU  - Hanyang Liu
AU  - Yawen Hao
AU  - Lanlan Chen
PY  - 2026
DA  - 2026/09/24
JO  - Diabetes, Obesity & Metabolism
DO  - 10.1111/dom.71391
UR  - https://doi.org/10.1111/dom.71391
SN  - 1462-8902
SN  - 1463-1326
ER  -